A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

NCT06224348 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

643

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis Atopic

Interventions

DRUG: Amlitelimab
DRUG: Placebo
DRUG: Topical corticosteroids
DRUG: Topical calcineurin inhibitors

Sponsor

Sanofi